

# ALT5 Sigma Signals Readiness as U.S. Stablecoin Legislation Passes into Law

written by Raj Shah | July 18, 2025

July 18, 2025 ([Source](#)) – ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) (“ALT5 or the “Company”), a fintech company delivering blockchain-powered payment and trading infrastructure for global merchants and financial institutions, today welcomed the signing of the GENIUS Act, a landmark U.S. law establishing a regulatory framework for stablecoin issuance and oversight.

“We believe this legislation marks a turning point,” said **Peter Tassiopoulos**, CEO of ALT5 Sigma. “With a clear legal foundation now in place, U.S. enterprises can finally build with confidence and unlock the transformative capabilities of blockchain.”

ALT5 infrastructure has been designed from the start to support responsible, compliant digital asset adoption at scale for compliance-first deployments; aligned with the principles now being codified in law. The company sees this legislation as a critical step toward leveling the playing field for regulated actors while protecting the industry from bad actors and systemic risk.

Stablecoins processed a staggering [\\$27.6 trillion USD in on-chain transactions](#) during 2024, surpassing the combined annual volumes for Visa and Mastercard. Their role in cross-border payments, remittances, and on-platform settlement continues to grow, particularly among fintechs and institutional users seeking efficiency and transparency.

ALT5 has processed over \$5 billion USD in cryptocurrency transactions to date, supporting more than 1,000 businesses worldwide. The company continues to see accelerating demand for [stablecoin-related infrastructure](#) as enterprises look to integrate blockchain-based payments into their existing operations.

The company supports responsible regulation and welcomes ongoing efforts by U.S. policymakers to bring greater structure and transparency to the digital asset ecosystem.

As adoption accelerates, this regulatory clarity is expected to streamline ALT5's continued growth in an expanding global market.

To learn more about how ALT5 supports institutional stablecoin integration, visit [www.alt5sigma.com](http://www.alt5sigma.com).

### **About ALT5 Sigma Corporation**

[ALT5 Sigma Corporation](#) (NASDAQ:ALTS)(FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets.

Founded in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: "ALT5 Pay" and "ALT5 Prime." The company has processed over \$5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay

payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.

The Company is also advancing the separation of its biotech business, which will continue under "Alyea Therapeutics Corporation." Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

### **Forward Looking Statements**

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit

risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also may contain statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the sections entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements.

Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

**Media/Investor Relations Contact**

[IR@alt5sigma.com](mailto:IR@alt5sigma.com)

1-800-400-2247